Regan K - Search Results

1

Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2.

Bluman LG, Rimer BK, Berry DA, Borstelmann N, Iglehart JD, Regan K, Schildkraut J, Winer EP. Bluman LG, et al. Among authors: regan k. J Clin Oncol. 1999 Mar;17(3):1040-6. doi: 10.1200/JCO.1999.17.3.1040. J Clin Oncol. 1999. PMID: 10071299 Clinical Trial.

2

Genetic testing for susceptibility to breast cancer: findings from women's focus groups.

Tessaro I, Borstelmann N, Regan K, Rimer BK, Winer E. Tessaro I, et al. Among authors: regan k. J Womens Health. 1997 Jun;6(3):317-27. doi: 10.1089/jwh.1997.6.317. J Womens Health. 1997. PMID: 9201666

3

Patient Motivation, Satisfaction, and Coping in Genetic Counseling and Testing for BRCA1 and BRCA2.

Clark S, Bluman LG, Borstelmann N, Regan K, Winer EP, Rimer BK, Skinner CS. Clark S, et al. Among authors: regan k. J Genet Couns. 2000 Jun;9(3):219-35. doi: 10.1023/A:1009463905057. J Genet Couns. 2000. PMID: 26141318

4

Ethical ramifications of alternative means of recruiting research participants from cancer registries.

Sugarman J, Regan K, Parker B, Bluman LG, Schildkraut J. Sugarman J, et al. Among authors: regan k. Cancer. 1999 Aug 15;86(4):647-51. doi: 10.1002/(sici)1097-0142(19990815)86:4<647::aid-cncr13>3.0.co;2-g. Cancer. 1999. PMID: 10440692

5

Androgen deprivation increases p300 expression in prostate cancer cells.

Heemers HV, Sebo TJ, Debes JD, Regan KM, Raclaw KA, Murphy LM, Hobisch A, Culig Z, Tindall DJ. Heemers HV, et al. Cancer Res. 2007 Apr 1;67(7):3422-30. doi: 10.1158/0008-5472.CAN-06-2836. Cancer Res. 2007. PMID: 17409453

6

CBP loss cooperates with PTEN haploinsufficiency to drive prostate cancer: implications for epigenetic therapy.

Ding L, Chen S, Liu P, Pan Y, Zhong J, Regan KM, Wang L, Yu C, Rizzardi A, Cheng L, Zhang J, Schmechel SC, Cheville JC, Van Deursen J, Tindall DJ, Huang H. Ding L, et al. Cancer Res. 2014 Apr 1;74(7):2050-61. doi: 10.1158/0008-5472.CAN-13-1659. Epub 2014 Feb 3. Cancer Res. 2014. PMID: 24491799 Free PMC article.

7

Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cells.

Dehm SM, Regan KM, Schmidt LJ, Tindall DJ. Dehm SM, et al. Cancer Res. 2007 Oct 15;67(20):10067-77. doi: 10.1158/0008-5472.CAN-07-1267. Cancer Res. 2007. PMID: 17942941

8

Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for serum response factor in prostate cancer.

Heemers HV, Regan KM, Dehm SM, Tindall DJ. Heemers HV, et al. Cancer Res. 2007 Nov 1;67(21):10592-9. doi: 10.1158/0008-5472.CAN-07-1917. Cancer Res. 2007. PMID: 17975004

9

Androgen modulation of coregulator expression in prostate cancer cells.

Heemers HV, Regan KM, Schmidt LJ, Anderson SK, Ballman KV, Tindall DJ. Heemers HV, et al. Mol Endocrinol. 2009 Apr;23(4):572-83. doi: 10.1210/me.2008-0363. Epub 2009 Jan 22. Mol Endocrinol. 2009. PMID: 19164447 Free PMC article.

10

Differential regulation of steroid nuclear receptor coregulator expression between normal and neoplastic prostate epithelial cells.

Heemers HV, Schmidt LJ, Kidd E, Raclaw KA, Regan KM, Tindall DJ. Heemers HV, et al. Prostate. 2010 Jun 15;70(9):959-70. doi: 10.1002/pros.21130. Prostate. 2010. PMID: 20166126 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

278 results

Search Page

Filters